Dariusz Godlewski - Academia.edu (original) (raw)

Uploads

Papers by Dariusz Godlewski

Reports of Practical Oncology & Radiotherapy, 1998

Diagnostics

epithelium cells are considered as promising diagnostic markers of cervical dysplasia. MicroRNA-b... more epithelium cells are considered as promising diagnostic markers of cervical dysplasia. MicroRNA-based diagnostic test-systems can provide a helpful addition to traditional diagnostic techniques. Methodology NOVAprep-miR-CERVIX is a new test-system based on RT-qPCR analysis of six miRNAs (miR-21-5p; miR-29b-3p; miR-145-5p; miR-451a-5p; miR-1246-5p and miR-1290-3p) in material of cervical smear. Test-system includes quality of material control and control of enzymatic reaction efficacy. Machine learning based of random forest algorithm was applied for RT-qPCR results evaluation. Cervical smear samples were obtained from 226 women: 114 samples of normal epithelium and 112 samples of cervical epithelium with high-grad intraepithelial lesion (HSIL) or carcinoma in situ (CIS) as a result of cytological evaluation. Moreover, any of HSIL/CIS diagnosis was confirmed histologically. Results The 38 samples from 216 (17.8%) did not pass quality controls and were excluded from analysis. NOVAprep-miR-CERVIX Index (miR-CERVIX-I varied from 0 to 1) was calculated on the base of results of six miRNA analysis for remaining 178 samples. Difference in miR-CERVIX-I was statistically significant in two groups of samples formed on the base of cytological/histological diagnosis (figure 1). Normal condition of cervical epithelium (miR-CERVIX-I < 0.49) was diagnosed with sensitivity 79.2%, specificity 80.46%. HSIL was diagnosed with sensitivity 70.83%, specificity 97.22% (miR-CERVIX -I > 0.78). Moreover, intermediate value of miR-CERVIX-I (between 0.5 and 0.77) is supposed to reflect condition of low-grade intraepithelial dysplasia.

Reports of Practical Oncology & Radiotherapy, 1998

Hereditary Cancer in Clinical Practice, 2012

To identify host and tumor factors which predict a complete pathologic response (pCR) after neoad... more To identify host and tumor factors which predict a complete pathologic response (pCR) after neoadjuvant treatment with cisplatin chemotherapy in women with breast cancer and a BRCA1 mutation.

European journal of gynaecological oncology, 2009

Ovarian and endometrial cancers seldom develop in females under 40 years of age. Manifestation of... more Ovarian and endometrial cancers seldom develop in females under 40 years of age. Manifestation of metachronic cancers before the age of 40 is of casuistic interest. Two cases are presented in whom metachronic cancers were detected: the first localisation involved the ovary, and the second the endometrium. One of the patients had earlier delivered a baby with multiple hereditary defects and was diagnosed with secondary infertility. The second patient was diagnosed with primary infertility. Immunohistochemical tests disclosed the presence of alpha and beta type estrogen receptors and progesterone receptors in the tumour cells of the ovary and endometrium. Neither of the patients carried mutations in the BRCA 1 or NOD 2 genes.

Reports of Practical Oncology & Radiotherapy, 2003

Reports of Practical Oncology & Radiotherapy, 1998

Reports of Practical Oncology, 1997

Reports of Practical Oncology & Radiotherapy, 1998

International Journal of Oncology, 1996

Cancer antigens RAK-pl20, p42, and p25, which exhibit biological, immunological and molecular sim... more Cancer antigens RAK-pl20, p42, and p25, which exhibit biological, immunological and molecular similarity to the proteins expressed by Human Immunodeficiency Virus 1 (HIV-1), were found in 47 of 47 tested cases of serous adenocarcinoma of the ovary, and 45 of 45 tested cases of squamous carcinoma of the cervix. Normal ovary and cervix did not express antigens RAK. High molecular weight protein (RAK-pl60) was detected in the blood of over 61% of ovarian and 72% of cervical cancer patients, and in 14.3% of healthy women with family history of breast and/or gynecological cancer. Antigens RAK might represent new diagnostic markers.

Breast Cancer Research and Treatment, 2013

To identify characteristic features of breast cancers associated with an NBS1 mutation. To estima... more To identify characteristic features of breast cancers associated with an NBS1 mutation. To estimate and to compare 10-year survival rates for patients with early-onset breast cancer, with and without an NBS1 mutation. 4,566 women with stage I to stage III breast cancer, diagnosed at or below age 50, were tested for a founder mutation in the NBS1 gene. Information on tumor characteristics and on treatments received was retrieved from medical records. Dates of death were obtained from the Poland vital statistics registry. Survival curves for the mutation-positive and negative sub-cohorts were generated and were compared and the effect of an NBS1 mutation on survival was determined using the Cox proportional hazards model. 4566 patients were enrolled in the study, of whom 53 (1.2 %) carried a NBS1 mutation. Mutation carriers were similar to non-carriers in terms of tumor receptor status, grade, and lymph node status. The 10-year survival for NBS1 mutation carriers was 81.2 % (95 % CI 70.1-94.1 %) and for non-carriers was 79.4 % (95 % CI 78.0-80.9 %). The presence of an NBS1 mutation is not associated with prognosis (HR = 1.21; 95 % 0.67-2.19). The survival of women with breast cancer and a NBS1 mutation is similar to that of patients without a NBS1 mutation.

Reports of Practical Oncology, 1996

Reports of Practical Oncology & Radiotherapy, 2003

Nutrients

Lack of consistency in the relationship between dairy products consumption and breast cancer (BC)... more Lack of consistency in the relationship between dairy products consumption and breast cancer (BC) risk motivated us to evaluate this association in a case-control study of BC among Polish women. The study includes 1699 women 26–79 years of age, 823 BC cases identified in Cancer Registries and 876 randomly selected controls from the national population registry. Using a validated, semiquantitative food frequency questionnaire (FFQ), the consumption of dairy products was collected for a time period of 10–15 years prior to BC diagnosis. We used logistic regression, adjusting for potential confounders, to assess the relationship between total dairy consumption as well as individual dairy groups of milk, cottage cheese and hard cheese and BC risk for premenopausal and postmenopausal women. For total consumption, a significant decrease in BC risk was observed with increased consumption of one serving/week, OR trend = 0.98, 2% decrease in risk, for premenopausal women only. For milk, a sig...

British Journal of Cancer, 2022

BACKGROUND To estimate the impact of oophorectomy and other treatments on the survival of breast ... more BACKGROUND To estimate the impact of oophorectomy and other treatments on the survival of breast cancer patients with a CHEK2 mutation. METHODS Women with Stage I-III breast cancer who were treated at 17 hospitals in Poland were tested for four founder mutations in the CHEK2 gene. 974 women (10%) were positive for a CHEK2 mutation. Control patients without a CHEK2 mutation were selected from a database of patients treated over the same time period. Information on treatments received and distant recurrences were retrieved from medical records. Treatments included chemotherapy, hormonal therapy (tamoxifen) and radiation therapy. Oophorectomies were performed for the treatment of breast cancer or for benign conditions. Dates of death were obtained from the Polish Vital Statistics Registry. Causes of death were determined by medical record review. Predictors of survival were determined using the Cox proportional hazards model. RESULTS In all, 839 patients with a CHEK2 mutation were matched to 839 patients without a mutation. The mean follow-up was 12.0 years. The 15-year survival for CHEK2 carriers was 76.6% and the 15-year survival for non-carrier control patients was 78.8% (adjusted HR = 1.06; 95% CI: 0.84-1.34; P = 0.61). Among CHEK2 carriers, the 15-year survival for women who had an oophorectomy was 86.3% and for women who did not have an oophorectomy was 72.1% (adjusted HR = 0.59; 95% CI: 0.38-0.90; P = 0.02). Among controls, the 15-year survival for patients who had an oophorectomy was 84.5% and for women who did not have an oophorectomy was 77.6% (adjusted HR = 1.03; 95% CI: 0.66-1.61; P = 0.90). CONCLUSION Among women with breast cancer and a CHEK2 mutation, oophorectomy is associated with a reduced risk of death from breast cancer.

in Wielkopolska in 2008 was one of the highest in the country and was higher than in Poland by 21... more in Wielkopolska in 2008 was one of the highest in the country and was higher than in Poland by 21 % in men and by 14 % in women. We can quantify the fu-ture burden of cancer from two different perspectives: the number of new cancer cases due to population change and new cases due to risk change. Making pre-dictions of number of new cancer cas-es in Wielko polska in 2018. Material and methods: These projections of number of cancer cases, age specif-ic rates and age-standardized rates for 2018 (all cancers and the most fre-quent cancers for men and women) has been based on the historical trends of cancer incidence in Wielkopolska in 1999-2008 and demographical progno-sis of Central Statistical Office using the method of Hakulinen and Dyba. Results: There will be over 8000 new can-cer cases in men in Wielkopolska in 2018 and over 7000 in women. Compare to the period 2004-2008 the number of can-cer cases will increase by 45 % for men and by nearly 30 % for women. About 2/3 of the increa...

Reports of Practical Oncology & Radiotherapy, 2003

Polish Journal of Surgery, 2011

in Poznań 2 Kierownik: prof. dr hab. m. Drews Center for Prevention and Epidemiology of Cancers O... more in Poznań 2 Kierownik: prof. dr hab. m. Drews Center for Prevention and Epidemiology of Cancers OPEN in Poznań 3 Dyrektor: dr n. med. D. Godlewski Screening of the colon cancer seems to be important to improve the results of the surgical treatment. There are different screening programs, the most common use the fecal occult blood (FOB) tests or colonoscopy. the aim of the study was to evaluate the results of the colon cancer screening based on the FOB test and perform the algorhytm improving the effectiveness of the screening. Material and methods. 941 patients with the positive results of the FOB (immunochromatographic method) test were investigated. In all cases the rectosigmoidoscopy for the detection of the lower GI tract pathology was done. 312 patients were qualified to colonoscopy. Results. Adenomatous polyps and adenocarcinomas were detected in 116 patients. There was no correlation between clinical symptoms and the colorectal cancer. The colorectal cancer was recognized statistically more common at the patients with previous detected neoplasia, in the colon and other organs, with hereditary nonpolyposis colorectal cancer and with inflammatory bowel diseases. conclusions. The colorectal cancer screening based on the FOB can be effective in the early recognition of the bowel malignancy. The previous questionnaire can eliminate from the FOB screening the patients without indications (previously done colonoscopy or barium enema) or with directly indications for colonoscopy.